Testing a new cancer-fighting injection for advanced lung and solid tumors

Plain-English translation of NCT07056556 on ClinicalTrials.gov ↗ · Source last updated August 2025 · Translation generated August 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage clinical trial (Phase I) testing a new medication called , given as an injection into the vein. The study will enroll about 31 patients with advanced lung cancer or other solid tumors that have not improved with standard treatments. Researchers want to understand how safe the medication is, how well patients tolerate it, and whether it helps shrink tumors.

Current standard treatments don't work for all patients with advanced cancer, and some people develop resistance to existing therapies. This medication uses a new approach, and researchers believe it could offer another option for patients whose cancer has progressed despite other treatments.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old (or 18 and older in the later phase)
you have been diagnosed with advanced or metastatic non-small cell lung cancer or another solid tumor that has not responded to standard treatment
you are expected to live at least 3 months
you have at least one measurable tumor on imaging
you are in good enough physical condition (ECOG score 0 or 1, meaning you can carry out most normal activities)
you are willing to provide a tumor tissue sample and agree to use effective birth control during and for 6 months after treatment

You likely don't qualify if…

you have received chemotherapy, immunotherapy, or other cancer treatments within the past 4 weeks
you have a history of severe heart disease, heart rhythm problems, or a very weak heart
you have an active autoimmune disease or active infection (including HIV, hepatitis B, or tuberculosis)
you have untreated or unstable brain metastases (cancer spread to the brain)
you have poorly controlled high blood pressure or diabetes, or a history of blood clots in the past 6 months

What participation looks like

You would receive the medication as an intravenous infusion (through a vein) in 3-week treatment cycles. If the medication appears to be helping and you tolerate it well, you can continue receiving additional cycles. Throughout the study, you'll have regular blood tests, imaging scans, and clinic visits to monitor how your cancer is responding and check for any side effects. The treatment will stop if your cancer progresses, you experience unmanageable side effects, or for other medical reasons determined by your doctor.

AI-generated summary from trial data · Aug 8, 2026 · Not medical advice

Trial locations(1 site)

China

Shanghai Chest Hospital, Shanghai, Shanghai Municipality